Nerve-muscle Communication Molecule May Be SBMA Therapeutic Target, Study Says
Increasing the levels of brain-derived neurotrophic factor (BDNF) — a molecule involved in the communication between nerve cells and…
Articles by Marta Figueiredo, PhD
Ohio Study Finds Zolgensma Safe, Effective, Particularly in Younger Infants
Novartis’ gene therapy Zolgensma is generally safe and effective in promoting motor improvements in children with spinal muscular atrophy (SMA)…
SMA Registries Offer ‘Real-world Experience’ That Makes Best Treatment Possible
[Editor’s Note: This is part of a series of articles about the discovery and development of Evrysdi —…
Comparing SMA Therapies Neither Easy Nor Fair, Clinicians Say
[Editor’s Note: This is part of a series of articles into the discovery and development of Evrysdi —…
Treatment Is Key for All With SMA, But Gains Will Differ
[Editor’s Note: This is part of a series of articles into the discovery and development of Evrysdi —…
Ways of Capturing Real-life Gains, True Value of SMA Therapy, Still Needed
[Editor’s Note: This is part of a series of articles into the discovery and development of Evrysdi —…
Evrysdi for SMA Under Accelerated Review in Europe
The European Medicines Agency (EMA) has accepted and is now reviewing Roche’s marketing authorization application (MAA) requesting approval of Evrysdi…
Muscle and Combo Therapies Likely Next Focus for SMA, Experts Say
[Editor’s Note: This is part of a series of articles into the discovery and development of Evrysdi, SMA’s…
SMA Debate: Might Systemic Treatment Be Best?
[Editor’s Note: This is part of a series of articles about the discovery and development of Evrysdi —…
Evrysdi and Spinraza Target SMN2 Gene, But in Different Ways
Although both Evrysidi (risdiplam) and Spinraza (nusinersen) work to correct the same issue in spinal muscular atrophy…